What Is KPV? Benefits, Research & Safety
An anti-inflammatory tripeptide derived from alpha-MSH, researched for potent NF-κB inhibition and applications in gut and skin inflammation.
UK summary: Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.
Quick Facts
Overview
KPV — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
- EU: Not approved by the EMA. Available as a research compound.
- Notes: KPV is not approved for therapeutic use in any major jurisdiction. Research use only.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Treats inflammatory bowel disease (Crohn's, ulcerative colitis).
- Heals leaky gut and food sensitivities.
- Treats psoriasis and eczema topically.
- Safe oral peptide with no side effects.
07Common internet claims
- Marketed by 'functional medicine' practitioners for gut healing.
- Sold by online retailers in oral capsule and topical formats.
- Promoted as a natural anti-inflammatory tripeptide.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures IBD / Crohn's / ulcerative colitis” | D | No | High | Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence. |
| “Heals leaky gut” | E | No | High | ‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Limited systematic safety data in humans.
- Theoretical risk of suppressing helpful immune responses.
- Unknown effects when used with biologics or immunosuppressants.
- Topical preparation quality (compounding) unverified.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
14EU legal position
Not approved by the EMA. Available as a research compound.
15What this page cannot tell you
- Whether a UK-purchased KPV product contains the tripeptide at the labelled concentration.
- Whether oral administration produces meaningful systemic exposure.
- How it interacts with biologics (anti-TNF) or steroids used in IBD.
- Whether the anti-inflammatory effect translates from cell culture to clinical disease.
16Last reviewed
17Citation quality score
18Research gaps
- No registered Phase 2 or 3 trials for IBD or any human condition.
- Pharmacokinetic data in humans absent.
- Long-term safety unstudied.
- Combination safety with licensed IBD treatments uncharacterised.
19Safer alternatives / established care pathways
- GP and gastroenterology referral for any persistent GI symptoms.
- NHS IBD pathway — anti-TNF biologics, mesalazine, steroids — all with extensive evidence.
- Dermatology referral for psoriasis or eczema, with licensed topical and biologic options.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is KPV a licensed UK medicine for IBD?
- What licensed IBD or GI treatments should I consider first?
- Should my GI symptoms be properly investigated?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent NF-κB inhibition reducing inflammatory gene expression
- 2Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- 3Potential applications in inflammatory bowel disease (colitis models)
- 4Anti-inflammatory effects in skin inflammation models
- 5Small size enabling oral and topical delivery possibilities
- 6Anti-inflammatory activity without melanogenic side effects
Claim vs Evidence
How popular claims about KPV stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Cures IBD / Crohn's / ulcerative colitis” | D | No | High | Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence. |
| “Heals leaky gut” | E | No | High | ‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Research protocols vary; oral and injectable routes studied |
| Frequency | Daily administration in most research protocols |
| Duration | Typically 2-4 weeks in preclinical studies |
| Notes | Nanoparticle formulations studied for targeted gut delivery. No established human dosing protocols exist. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection
- Oral (research)
- Topical (research)
- Nanoparticle delivery (research)
| Half-Life | Stability |
|---|---|
| Short half-life typical of small peptides; exact pharmacokinetic data limited | Relatively stable for a tripeptide; lyophilised form recommended for storage |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Injection site reactions (injectable route)
- Limited human safety data available
Rare Risks & Concerns
- Unknown long-term effects
- Potential immune suppression with chronic use
Contraindications
- Active infections (theoretical)
- Immunocompromised states
- Pregnancy and breastfeeding
UK & EU Regulatory Context
🇬🇧 United Kingdom
Unregulated research peptide. Not approved for human therapeutic use by the MHRA.
🇪🇺 European Union
Not approved by the EMA. Available as a research compound.
Clinical Studies Summary
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.
Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.
Collectively, tripeptides represent a promising class of multifunctional bioactive molecules in wound care, offering novel avenues for targeted tissue regeneration. Future research should focus on improving their stability, bioavailability, and delivery systems to fully harness their clinical potential in regenerative medicine.
Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.
HDPs have immunoregulatory mechanisms, downregulating the nuclear factor kappa B (NF-κB) pathway, modulating cytokine release, and restoring homeostasis. The data suggest that HDPs have therapeutic potential for IBDs, offering a way to reduce side effects, and we focus on this issue here.
Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.
KdPT, a derivative of KPV corresponding to IL-1β(193-195), currently is emerging as another tripeptide with potent anti-inflammatory effects.
Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
KdPT, a derivative of KPV corresponding to amino acids 193-195 of IL-1beta, is also emerging as a tripeptide with antiinflammatory effects. The physiochemical properties and expected low costs of production render both agents suitable for the future treatment of immune-mediated inflammatory skin and bowel disease, fibrosis, allergic and inflammatory lung disease, ocular inflammation, and arthritis.
New insights into the functions of alpha-MSH and related peptides in the immune system.
These effects were mediated via IL-10 production, because IL-10 knockout mice were resistant to alpha-MSH treatment. Therefore, therapeutic application of alpha-MSH or related peptides (KPVs) as well as alpha-MSH/KPV-pulsed DCs may be a useful approach for the treatment of inflammatory, autoimmune, and allergic diseases in the future.
Looking for KPV?
Source research-grade KPV from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about KPV
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is KPV a licensed UK medicine for IBD?
- What licensed IBD or GI treatments should I consider first?
- Should my GI symptoms be properly investigated?
UK regulatory & safety context
Related Research Guides
Related Peptides
BPC-157
A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.
Learn moreThymosin Alpha-1
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
Learn moreLL-37
The only human cathelicidin antimicrobial peptide, with broad-spectrum antimicrobial activity and important immunomodulatory functions.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn moreAlpha-MSH
A melanocortin peptide with pigmentation, anti-inflammatory, and appetite-regulating effects, the natural basis for several therapeutic developments.
Learn more